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The nomenclature describing hematopoietic stem cell transplantation has evolved, adding precision and
deﬁnition in research and regulation. The lack of coordination and standardization in terminology has left
some gaps in the deﬁnition of episodes of clinical care. These voids have caused particular problems in
contracting for payment and billing for services rendered. The purpose of this report is to propose deﬁnitions
for cell products, cell infusions, and transplantation episodes.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Terminology (CPT) codes also describe the physician
Rapid progress in the clinical development of cellular
therapies has fostered a dramatic expansion in the applica-
tion of hematopoietic stem cell transplantation (HSCT) to
new diseases and patient populations. This expansion is
evident in the ﬁnding of the Agency for Healthcare Research
and Quality that blood and marrow transplantation had the
largest associated percentage cost increase of any inpatient
hospital procedure in the United States for the period 2004-
2007 [1].
The terminology used to describe the cell products and
the corresponding procedures is also evolving to address
clinical, regulatory, and ﬁnancial needs. There are clear
deﬁnitions of individual cell products recognized by the
United States Food and Drug Administration and such
agencies as the Foundation for the Accreditation of Cellular
Therapy, the AABB, and the Center for International Blood
andMarrow Transplant Research (CIBMTR) have clariﬁed the
application of these terms as they apply to clinical research
[2,3]. Reimbursement code systems, including the Medicare
severity diagnosis-related groups used by the Centers for
Medicare and Medicaid Services and the International Clas-
siﬁcation of Diseases codes, encompass broad deﬁnitions of
stem cell transplantation contained within very few codes.
Various American Medical Association Current Proceduraldgments on page 853.
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13.03.004component in the acquisition (CPT 38205, 38206, 38230, and
38232) and subsequent infusion (CPT 38240-38243) of
cellular products. The CPT codes have precise deﬁnitions that
must be followed for billing of physician services and
hospital services on the day of the procedure (data not
shown). Finally, the terminology of the methods used to
prepare a patient for HSCT has also undergone evolution [4].
Although the nomenclature describing HSCT has under-
gone modiﬁcations that have added precision to deﬁned
areas of research and regulation, the lack of coordination and
standardization of terms has left clinical gaps in the deﬁni-
tion of episodes of care. These voids have become particu-
larly problematic for administrative purposes, such as
contracting for payment and billing for services rendered.
The purpose of this report is to propose standard deﬁnitions
for cell products, cell infusions, and transplantation episodes.
Implications for contracting for transplantation services are
discussed.PROCESS
In collaboration with the National Marrow Donor
Program, the American Society for Blood and Marrow
Transplantation established a task force to address the cell
infusion deﬁnitions associated with deﬁning and contracting
for episodes of transplantation care. The task force convened
a panel of transplantation physicians, health plan/trans-
plantation network representatives, and additional stake-
holders to discuss the need for more deﬁned language and
generate common deﬁnitions of various cell infusionTransplantation.
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several sources, as well as those developed by meeting
participants. Applicable reimbursement codes (International
Classiﬁcation of Diseases, CPT, and diagnosis-related groups)
were mapped to draft deﬁnitions and ﬂagged for potential
issues. Aims of procedures, technical deﬁnitions, and corre-
sponding reimbursement coding system information were
also considered by the panel.
PROCEDURE DEFINITION
The task force’s recommendations for standardization of
procedure deﬁnitions are summarized in Appendix A. There
was consensus that procedure terminology lacked stan-
dardization and was being used for differing purposes.
Recognizing that the CIBMTR created a series of procedural
deﬁnitions describing only the types of infusions as a means
to clarify therapeutic and research efforts, the task force
nevertheless recommends that these deﬁnitions serve as the
foundation for its recommendations for descriptions of
episodes of care [3].
The term “hematopoietic stem cell infusion” (HSCI) is
recommended to describe the infusion of a product that
contains hematopoietic progenitor cells (ie, bone marrow,
peripheral blood stem cells, or umbilical cord blood) inten-
ded to restore hematopoiesis or immunity. “Hematopoietic
stem cell transplantation” (HSCT) is deﬁned as HSCI
commonly performed after administration of a preparative
regimen. “Allogeneic HSCT” is deﬁned as allogeneic HSCI
infused most commonly after a preparative regimen of
variable intensity. Allogeneic HSCT may be performed
without a preparative regimen in selected clinical situations,
such as the treatment of some immunodeﬁciency disorders.
“Syngeneic HSCT” is an uncommon type of HSCT inwhich the
recipient receives an HSCI from an identical twin. Clinical
management of recipients of syngeneic HSCT is similar to
that of autologous HSCT, although complications typical of
allogeneic HSCT may occur infrequently. As with other allo-
geneic HSCTs, the identical-twin donor must still be evalu-
ated and qualiﬁed before harvesting of the stem cell product.
Although traditionally considered a transplantation
procedure, some investigators are now questioning whether
autologous HSCI after chemotherapy is consistent with the
broader deﬁnition of transplantation (ie, transfer of an organ
or tissue from one part of the body to another or from one
person to another). This consideration is important for
2 reasons. First, distinguishing the infusion of a cell product
from the episode of care encompassing high-dose chemo-
therapy and autologous HSCI is necessary for deﬁning and
contracting for the resources needed to deliver quality
patient care. Second, there is a need to distinguish these
procedures from others in which less-intensive chemo-
therapy is delivered with HSCI support or even without
chemotherapy as somatic cell therapy. The task force
proposes that autologous HSCT be deﬁned as always
preceded by a myeloablative preparative regimen. In turn,
a myeloablative preparative regimen is deﬁned as “a
combination of agents expected to produce profound
pancytopenia and myeloablation within 1-3 weeks of
administration; pancytopenia is long-lasting, usually irre-
versible, and in most instances fatal, unless hematopoiesis is
restored by hematopoietic stem cell infusion” [4]. Although
this deﬁnition varies somewhat from that of the CIBMTR, the
intent is to distinguish autologous HSCT from autologous
HSCI performed after each cycle of multiple cycles of non-
myeloablative chemotherapy, to prevent marrow exhaustion[2]. It should also encompass settings in which tandem
transplantations may be considered standard of care, such as
the treatment of multiple myeloma and testicular cancer.
The term “retransplantation” refers to a subsequent HSCT
after a primary autologous or allogeneic HSCT. The recipient
will typically require reevaluation and qualiﬁcation, and
must meet the institution’s eligibility requirements for
transplantation. The transplantation procedure also must
meet the previously proposed criteria for allogeneic or
autologous HSCT. Retransplantation is typically performed
more than 3months after the ﬁrst HSCT, and HSCI is typically
provided at the completion of the preparative regimen on
day 0. These deﬁnitions should be compatible with the
primary transplantation infusion CPT codes 38240
and 38241.
Various terms, including “boost,” “reinfusion,” “support,”
and “rescue,” have been used to describe an HSCI provided to
a transplantation recipient after the initial transplantation to
assist with hematopoietic recovery or declining donor
chimerism. The task force strongly endorses “boost” as the
preferred term for either autologous or allogeneic HSCI for
this indication and recommends eliminating other terms.
The term “boost” is already linked to CPT 38243. A boost is
not preceded by a preparative regimen. A potential source of
confusion is that a boost is often required when additional
conventional chemotherapy is given to treat relapse and
reestablish remission after transplantation. Prolonged cyto-
penias and immunosuppression may result, requiring addi-
tional HSCI, which is typically given days to weeks after
reinduction chemotherapy.
The cell product used for HSCI in either a retrans-
plantation or a boost may be a previously cryopreserved cell
product that contains stem cells. Alternatively, the donor
may need to undergo additional evaluation, stem cell
mobilization, and cell harvest.
A donor cell infusion (DCI) is a cell product used as
immunotherapy to treat infections (eg, viral), recurrent
disease, or graft-versus-host disease. Standard cell products
include peripheral blood mononuclear cells and lympho-
cytes, whereas investigational DCI includes dendritic cells,
T regulatory cells, natural killer cells, mesenchymal cells, and
others currently in development. Themost common DCI, and
the only one with an associated CPT code (CPT 39242), is
donor lymphocyte infusion. Previously cryopreserved cell
products such as those collected for HSCI contain the cell
populations of interest and may be used for DCI, but the
intent is not to restore hematopoiesis. The recipient does not
receive a preparative regimen, but may require concomitant
therapy for the underlying problem.
The task force endorsed the description of “supplemental
infusion” as deﬁned by CIBMTR. These cell products are given
before day 0 of HSCT for any reason other than to produce
engraftment. A supplemental infusion is distinct from a DCI,
in that a DCI is given after HSCT. Presently there are no
standard indications for supplemental infusions, but inves-
tigational cell products include natural killer cells, regulatory
T lymphocytes, and mesenchymal cells.
The task force also reviewed the terms describing
preparative regimens and endorsed the recommendations of
the CIBMTR [4]. The preferred terms for preparative regi-
mens are “myeloablative,” “nonmyeloablative,” and
“reduced-intensity conditioning.” Terms that have been
commonly used such as “mini-transplant” and “lite” trans-
plantation are nonspeciﬁc colloquial references that have
been applied to both nonmyeloablative and reduced-
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strongly recommends that these terms be eliminated to
avoid confusion.
The applicable reimbursement codes associated with the
various infusion types are listed in Appendix B. A decision
tree providing a visual overview of the procedures is
provided in Appendix C.
IMPLICATIONS FOR CONTRACTING
Along with promoting scientiﬁc and regulatory accuracy,
the terminology deﬁning the elements of care surrounding
HSCT must encompass the necessary resources to deliver,
and contract for, care of the patient. Because healthcare
ﬁnancing relies on proper identiﬁcation and coding of
procedures, the lack of clarity in HSCT terminology pertain-
ing to the elements of care has created confusion in the
development and management of contracts with payors. For
example, some payor contracts depend on CPT codes to
trigger payment for an entire episode of HSCT care; however,
the CPT codes describe physicianwork and hospital payment
coding pertaining only to cell infusions. This has created
a risk that payment for an entire transplantation episode
might be delivered for a cell infusion remote from the
transplantation itself.
The task force recommends that the term “HSCT” refer to
the entire episode of care and all associated processes
including pretransplantation evaluation, preparative regi-
mens, HSCI, post-infusion supportive care, and immuno-
suppression. HSCT is now commonly reimbursed based on
global or case rates for the entire episode of care, typically for
a period of 30-100 days. Anticipated infusions such as HSCI
or DCI, if preplanned, should be described and included in
the case rate. Cell infusions that are not part of the initial
treatment plan, such as a boost for poor graft function or DCI
for incomplete chimerism occurring outside of the contract
period, should be negotiated separately. Payment for an
entire case rate should be based on the intent of the proce-
dure(s) and resources involved and should not be dictated
solely by the inclusion of speciﬁc CPT codes in the claim.
Although incomplete, the HSCT-associated CPT codes are
useful in deﬁning elements of care for contracting. Collectioncodes (CPT 38205, 38206, 38230, and 38232) can be helpful
for contract interpretation and collection. Cell processing
codes are useful in deﬁning the contracted techniques (CPT
38207-38215). The infusion codes (CPT38240-38243) should
be used only to describe services on the date of infusion, not
for the entire episode of care.
CONCLUSION
These recommendations for standardization of the terms
describing of cell products and types of HSCT are intended
to provide a framework that will facilitate clarity in the
deﬁnition of the programmatic resources required for an
episode of care for the patient, as well as contracting
discussions with payors. The hope is that they will also
serve as a foundation for the vast potential of cellular
therapies going forward.
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Appendix A
Recommended Procedure Terms and Deﬁnitions
Term Deﬁnition Intent Additional Notes Sample Clinical Scenario
HSCI Infusion of a product (bone marrow,
peripheral blood stem cells, cord blood) that
contains hematopoietic progenitor cells
(HPCs), often characterized by CD34
expression.
To restore hematopoiesis and immunity. Usually preceded by a preparative regimen
for HSCT or retransplantation, but also may
be used for a boost.
HSCT An episode of care starting with
a preparative regimen and continuing
through HSCI and recovery.
Allogeneic HSCT HSCI using products collected from a donor
and usually following a preparative
regimen. Donors may be a biological
relative of the recipient or anonymous and
unrelated.
Provided after a preparative regimen is
administered, regardless of intensity, or in
the absence of a preparative regimen in
selected clinical situations, such as
treatment of immunodeﬁciency.
A patient with acute myelogenous leukemia
in ﬁrst complete remission prepared with
busulfan and cyclophosphamide in
standard doses, followed by HSCI with bone
marrow from a matched unrelated donor.
Syngeneic HSCT HSCI using products collected from an
identical sibling.
Donor is an identical twin. Patient is
generally managed as an autologous HSCT
recipient. However, the identical twin
donor must still be evaluated and undergo
stem cell harvest, so the transplantation
should be categorized as allogeneic. Graft-
versus-host disease remains a possibility in
these cases.
Autologous HSCT HSCI using products collected from the
recipient before myeloablative
chemotherapy.
A patient with non-Hodgkin lymphoma
prepared with BEAM followed by
autologous HSCI with ﬁlgrastim
mobilization, infused with cryopreserved
peripheral blood HSCs.
Tandem transplantation Peripheral blood hematopoietic stem cells
(HSCs) are collected either during recovery
of a cycle of induction chemotherapy or
after ﬁlgrastim mobilization. The patient
receives a second preparative regimen,
along with HPCs collected during the initial
mobilization. Both transplantations are
planned in advance and typically are
performed a few weeks to a few months
apart.
To prevent marrow exhaustion. A patient with relapsed testicular cancer




Repeated cycles of intensive chemotherapy
followed by HSCI.
Involves single stem cell mobilization and
division of the collected stem cell product
into multiple cryopreserved aliquots. This is
followed by repeated cycles of intensive,
but often reduced-intensity, conditioning
regimens supported by stem cell infusion
meant to expedite hematologic recovery,
allowing for prompt administration of
a subsequent intensive cycle of
chemotherapy.
A patient with a disease process such as
neuroblastoma, central or peripheral

















DCI An infusion of cells from an allogeneic
donor typically given after HSCT. Types of
cells used for DCI include, but are not
limited to, the following:
 Lymphocytes/T cells (donor lymphocyte
infusion): a therapeutic product from any
source containing a quantiﬁed T cell
population
 Peripheral blood mononuclear cells (both
stimulated and unstimulated): whole
blood collected as a source of nucleated
cells intended for therapeutic use other
than HPCs
 Dendritic cells from the original donor:
a therapeutic cell product containing
dendritic cells for therapeutic use
 Mesenchymal cells: a therapeutic
product containing mesenchymal
stromal cells for therapeutic use
DCI is a form of immunotherapy commonly
used to treat infections (eg, viral) or
recurrent disease. DCI also may be used to
treat graft-versus-host disease or to
promote engraftment or enhancement of
chimerism when studies reveal <100%
donor cells. The recipient does not undergo
a preparative regimen before receiving the
additional donor cells, but may receive
additional preinfusion treatment.
The product may contain HSCs, but the
restoration of hematopoiesis is generally
not the primary intent of the infusion. CPT
38242 is assigned for allogeneic lymphocyte
infusions.
A patient with acute myelogenous leukemia
who underwent allogeneic HSCT and
relapsed at 6 months posttransplantion
without graft-versus-host disease. If stored
cells were not cryopreserved from the
donor, then the original donor undergoes
apheresis to collect T cells to give back to
the recipient. Any extra cells from the initial
collection are cryopreserved in a freezer
bottle at the transplantation center. Dosing
of these cryopreserved cells is based on T
cell doses of product infused, not on HSC
dose. Sometimes limited chemotherapy
precedes these infusions.
Cell types, standard: T cells (donor
lymphocyte infusion), peripheral blood
mononuclear cells; investigational:
dendritic cells, mesenteric stem cells.
Supplemental infusion An infusion of cells given before clinical day
0 (day of HSCT) for any reason other than to
produce engraftment. An infusion of
supplemental cells is often given in
conjunction with a preparative regimen for
HSCT.
Used for any reason other than to produce
engraftment.
A supplemental infusion differs from a DCI
in being given before HSCT, whereas a DCI is
given after HSCT. Examples of supplemental
infusions include, but are not limited to,
natural killer cells, T regulatory cells, and
mesenchymal stem cells.
An investigational study involving infusion
of CD3+- CD19+- selected and IL-2e
activated, haploidentical donor natural
killer cells on day 12 before a standard
preparative regimen and matched sibling
allogeneic HSCI.
Retransplantation HSCT after undergoing a previous
transplantation.
Requires requaliﬁcation of patient for
transplantation; transplantation must meet
the deﬁnition for allogeneic or autologous
HSCT.
A patient who relapses after initial HSCT
and is placed back into remission with
additional induction chemotherapy. The
patient is then requaliﬁed for HSCT.
Collection of additional HSCs may be
required in the setting of allogeneic HSCT.
Subsequent (boost) infusion Subsequent transfusion of allogeneic or
autologous HSCs.
Used in cases of weak hematopoiesis in an
attempt to augment the original graft.
“Boost” is the primary term used for this
procedure. A boost is not preceded by
a conditioning regimen. CPT 38243 is
assigned to HSC boost. May require the
recipient and/or donor to undergo
additional workup, mobilization, harvest/
procurement, and ultimately HSC infusion,
procedures also associated with subsequent
HSCT. A boost is not preceded by
a preparative regimen, but may be provided
days to weeks after induction
chemotherapy. Retransplantion commonly
involves a conditioning regimen directly
followed by HSC infusion (ie, on day 0).
An allogeneic HSCT recipient has 100%
donor cells but with a weak or poorly
functioning hematopoietic graft and low
peripheral blood counts. Excess
cryopreserved cells collected at the time of
transplantation would be infused.
A patient with acute myelogenous leukemia
who received a busulfan/cytoxan-
containing preparative regimen before
allogeneic HSCT. Approximately 4 months
after HSCT, the patient has severe
cytomegalovirus and fungal infections, but
with 100% donor cells, 10% cellularity on
bone marrow biopsy, an absolute
neutrophil count <1000, and platelet and
RBC transfusion-dependency. Extra cells
have been cryopreserved, or more fresh
cells are collected from the donor with
granulocyte colony-stimulating factor
mobilization. These cells are infused with
the intent of fully recovering
hematopoiesis. Dosing is based on the CD34

















Infusion Types and Associated Reimbursement Codes
Term International Classiﬁcation of
Diseases 9 Procedure Codes
CPT Codes MS-DRG
Autologous HSCT/HSCI
 Single autologous HSCT
 Tandem autologous HSCT
 Multiple-cycle autologous
 Retransplantation (autologous)
41.01: Autologous bone marrow
transplantation without purging
41.04: Autologous hematopoietic
stem cell transplantation without
purging
41.07: Autologous hematopoietic
stem cell transplantation with
purging

















41.02: Allogeneic bone marrow
transplantation with purging
41.03: Allogeneic bone marrow
transplantation without purging
41.05: Allogeneic hematopoietic
stem cell transplantation without
purging
41.06: Cord blood stem cell
transplantation
41.08: Allogeneic hematopoietic




014: Allogeneic bone marrow
transplantation
Supplemental infusion 99.09: Transfusion of other
substance
No MS-DRG assignment based on
this code. The DRG assignment is
driven by other codes submitted as
part of the inpatient stay.




No MS-DRG assignment based on
this code. The DRG assignment is
driven by other codes submitted as
part of the inpatient stay.
Subsequent (boost) infusion 99.09: Transfusion of other
substance
38243: HPC; HPC boost No MS-DRG assignment based on
this code. The DRG assignment is
driven by other codes submitted as
part of the inpatient stay.
MS-DRG indicates Medicare severity diagnosis-related group.
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Appendix C. Infusion Decision Tree.
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